Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00527566 · ClinicalTrials.gov registry record · Phase 1
Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome
A Phase 1 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00527566 is a Phase 1 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 10 participants.
The verdict
NCT00527566, a Phase 1 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Mepolizumab (a monoclonal antibody against interleukin-5) is a safe and well-tolerated therapy that will allow for steroid tapering in patients with steroid-dependent Churg-Strauss Syndrome (CSS).
Interventions
- BIOLOGICAL Mepolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00527566
The ClinicalTrials.gov registry entry for NCT00527566 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mepolizumab is the first listed.
NCT00527566 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00527566 about?
NCT00527566 is a clinical study titled "Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome". The purpose of this study is to determine whether Mepolizumab (a monoclonal antibody against interleukin-5) is a safe and well-tolerated therapy that will allow for steroid tapering in patients with steroid-dependent Churg-Strauss Syndrome (CSS).
What is the current status of trial NCT00527566?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2007-09. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00527566?
The interventions under investigation include: Mepolizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00527566?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.